Bacilysocin, a novel phospholipid antibiotic produced by Bacillus subtilis 168.

Antimicrobial Agents and Chemotherapy
Norimasa TamehiroKozo Ochi

Abstract

We have found a novel phospholipid antibiotic (named bacilysocin) which accumulates within (or associates with) the cells of Bacillus subtilis 168 and determined the structure by nuclear magnetic resonance and mass spectrometry analyses. The structure of bacilysocin elucidated was 1-(12-methyltetradecanoyl)-3-phosphoglyceroglycerol. Bacilysocin demonstrated antimicrobial activity, especially against certain fungi. Production of bacilysocin commenced immediately after growth ceased and before the formation of heat-resistant spores. The production of bacilysocin was completely blocked when the ytpA gene, which encodes a protein homologous to lysophospholipase, was disrupted, but blockage of the ytpA gene did not significantly affect growth. Sporulation was also impaired, with a 10-fold reduction in heat-resistant spore titers being detected. Since the ytpA disruptant actually lacked phospholipase activity, we propose that the YtpA protein functions as an enzyme for the biosynthesis of bacilysocin.

References

Oct 1, 1990·Journal of Industrial Microbiology·Gülay OzcengizA L Demain
Jan 1, 1991·Methods in Enzymology·K Karasawa, S Nojima
Oct 1, 1984·Journal of General Microbiology·Kozo Ochi, S Ohsawa
Jan 1, 1997·Applied and Environmental Microbiology·D VollenbroichJoachim Vater

Citations

Apr 30, 2011·Biotechnology Letters·Estibaliz Sansinenea, Aurelio Ortiz
Mar 16, 2011·Journal of Natural Products·Ahlem HamdacheIsidro G Collado
Feb 18, 2012·Natural Product Research·Salem ElkahouiHartmut Laatsch
Aug 28, 2007·Journal of Bacteriology·Mark A StrauchYoann Le Breton
May 18, 2006·Annual Review of Microbiology·Xiaorong Lin, Joseph Heitman
Jun 26, 2007·Bioscience, Biotechnology, and Biochemistry·Kozo Ochi
Aug 4, 2011·PloS One·Anna Maria HerznerGabriele Bierbaum
Mar 29, 2011·Journal of Environmental Management·Petri SusiTimo Korpela
Apr 28, 2005·Molecular Microbiology·Torsten Stein
Aug 15, 2008·Journal of Basic Microbiology·Lisana Reginini SirtoriAdriano Brandelli
Jan 9, 2008·Molecular Microbiology·Warawan Eiamphungporn, John D Helmann
May 6, 2011·Molecular Microbiology·Anthony W KingstonJohn D Helmann
Jan 15, 2010·FEMS Microbiology Letters·Olfa TabbeneFerid Limam
Sep 16, 2015·Antimicrobial Agents and Chemotherapy·Shigeo TojoKozo Ochi
Aug 30, 2018·Mini Reviews in Medicinal Chemistry·Aurelio Ortiz, Estibaliz Sansinenea
Aug 5, 2020·Archives of Microbiology·Lakshmi RajanRekha Devi Chakraborty
Sep 29, 2017·3 Biotech·Monika SinghKapil Deo Pandey
Jun 6, 2020·Frontiers in Bioengineering and Biotechnology·Ayomide Emmanuel Fadiji, Olubukola Oluranti Babalola
May 28, 2021·Frontiers in Molecular Biosciences·Jessica R Willdigg, John D Helmann

Related Concepts

Related Feeds

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.